NeuroPace
Venture Round in 2013
NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.
OptiScan Biomedical
Private Equity Round in 2013
OptiScan Biomedical Corporation specializes in developing advanced glucose monitoring systems for use in intensive care units. The company is known for its OptiScanner 5000, an automated bedside platform that provides precise plasma-based glucose measurements using spectroscopy technology, eliminating the need for calibration. This system enables healthcare providers to monitor and respond to changes in glucose levels for critically ill patients effectively. Founded in 1994 and headquartered in Hayward, California, OptiScan Biomedical faced financial challenges, filing for Chapter 11 bankruptcy in June 2020 and subsequently converting to Chapter 7 bankruptcy in November 2020.
Pulmonx
Private Equity Round in 2012
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
NeuroPace
Venture Round in 2011
NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.
Spinal Modulation
Series D in 2011
Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.
PolyRemedy
Series C in 2011
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
Activaero
Series A in 2011
Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.
Sonoma Orthopedic Products
Series D in 2011
Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.
Game Ready
Debt Financing in 2010
Game Ready is a medical device maker focused on treating post-surgical orthopedic sports injuries. The company operates primarily through its flagship product GameReady. The GameReady device essentially provides ice cold water and pressure to injured joints/body parts.
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
eNeura Therapeutics
Venture Round in 2010
eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.
Spinal Modulation
Series C in 2009
Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.
Sleep Solutions
Series F in 2009
Sleep Solutions is a privately held company specializing in the diagnosis and evaluation of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The firm offers a home-testing service that provides a fast, cost-effective, and accurate alternative to traditional in-laboratory sleep studies. Utilizing proprietary sound analysis technology, Sleep Solutions delivers its NovaSom QSG home-diagnostic system directly to patients, enhancing convenience and comfort. In addition to diagnosis, the company also focuses on therapy and compliance management related to sleep-disordered breathing, ensuring comprehensive care for patients.
BeneChill
Series C in 2009
BeneChill, Inc. is a medical device company based in San Diego, California, specializing in non-invasive cooling technologies aimed at enhancing patient outcomes following acute ischemic events, including cardiac arrest, stroke, and traumatic brain injury. Established in 2004, BeneChill has developed the RhinoChill System, which effectively reduces patient temperature to improve survival rates and recovery. The company operates primarily in the United States and Europe, focusing on innovative solutions for the healthcare sector.
SpinalMotion
Series C in 2009
SpinalMotion is a private company focused on preserving spinal motion for patients suffering from degenerative disc disease. Founded in 2004, the company specializes in the development of innovative artificial disc implants that utilize proprietary Kineflex Technology, designed to maintain the natural movement of the spine while offering low wear and improved longevity. Since obtaining FDA approval in 2005 to conduct clinical trials for lumbar and cervical artificial discs in the United States, SpinalMotion has built on its international clinical experience to enhance patient outcomes. The company has attracted investment from notable partners, including Southern Medical, Three Arch Partners, Skyline Ventures, and MedVenture Associates, to further its mission of enabling patients to lead pain-free and healthy lives.
NanoVasc is a pioneering medical device company specializing in the design and manufacture of biomimetic materials. These materials are engineered to be non-thrombogenic, durable, and capable of maintaining long-term patency. Utilizing an electrospinning process, NanoVasc produces scaffolds in various shapes and sizes, which are then customized with application-specific modifications on the scaffold's surface. These modifications are meticulously crafted to optimize device performance based on its intended deployment location. The company's flagship product is a synthetic vascular graft specifically developed for hemodialysis access. This innovative graft aims to improve patient outcomes by providing a reliable and effective alternative to traditional vascular access methods. NanoVasc's dedication to biomimetic design and precision engineering underscores its commitment to advancing medical solutions that enhance the quality of patient care in vascular health.
PolyRemedy
Series B in 2008
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
Amnis Corporation
Series C in 2008
Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.
Pavad Medical
Series C in 2007
PAVAD Medical, Inc., a medical device startup company, develops therapeutic technologies in the areas of obstructive sleep apnea. The company was incorporated in 2002 and is based in Fremont, California.
Game Ready
Venture Round in 2007
Game Ready is a medical device maker focused on treating post-surgical orthopedic sports injuries. The company operates primarily through its flagship product GameReady. The GameReady device essentially provides ice cold water and pressure to injured joints/body parts.
BeneChill
Series B in 2007
BeneChill, Inc. is a medical device company based in San Diego, California, specializing in non-invasive cooling technologies aimed at enhancing patient outcomes following acute ischemic events, including cardiac arrest, stroke, and traumatic brain injury. Established in 2004, BeneChill has developed the RhinoChill System, which effectively reduces patient temperature to improve survival rates and recovery. The company operates primarily in the United States and Europe, focusing on innovative solutions for the healthcare sector.
Intact Medical
Series G in 2007
Intact Medical Corporation specializes in the design, development, and marketing of minimally invasive systems for the volumetric excision of tissue, primarily targeting diagnostic and therapeutic applications in specific cancer markets. Founded in 1998 and based in Framingham, Massachusetts, the company offers an innovative intact breast lesion excision system. This system employs a vacuum-assisted, image-guided procedure that utilizes a slender wand inserted through a small incision to extract an intact sample of suspicious breast tissue. The procedure incorporates radio frequency energy, allowing for the complete removal of identified abnormalities with minimal invasiveness. Intact Medical's mission focuses on alleviating pain, restoring health, and extending life for patients undergoing treatment.
Sonoma Orthopedic Products
Series B in 2007
Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
EKOS Corporation is a pioneering company focused on the clinical application of ultrasound accelerated thrombolysis for the treatment of vascular thrombosis. Since its inception in 2005, EKOS has developed innovative technologies, including the EkoSonic Endovascular System, which utilizes microsonic technologies for the controlled and selective infusion of fluids specified by physicians. This system is employed by interventional radiologists, cardiologists, and vascular surgeons at leading medical institutions worldwide, enabling faster, safer, and more complete dissolution of thrombus, thereby enhancing patient outcomes in vascular care.
Asthmatx, Inc. is a medical device company based in Mountain View, California, that specializes in the development and commercialization of therapeutic treatments for asthma. Founded in 2003, the company has created a technology that delivers controlled thermal energy to the airways of adult patients, aimed at reducing the mass of airway smooth muscle through a procedure known as Bronchial Thermoplasty. Asthmatx offers the Alair System, an interventional medical device designed for bronchoscopic treatment of patients suffering from moderate to severe asthma. As of October 2010, Asthmatx operates as a wholly-owned subsidiary of Boston Scientific.
Pavad Medical
Series B in 2005
PAVAD Medical, Inc., a medical device startup company, develops therapeutic technologies in the areas of obstructive sleep apnea. The company was incorporated in 2002 and is based in Fremont, California.
OptiScan Biomedical
Venture Round in 2005
OptiScan Biomedical Corporation specializes in developing advanced glucose monitoring systems for use in intensive care units. The company is known for its OptiScanner 5000, an automated bedside platform that provides precise plasma-based glucose measurements using spectroscopy technology, eliminating the need for calibration. This system enables healthcare providers to monitor and respond to changes in glucose levels for critically ill patients effectively. Founded in 1994 and headquartered in Hayward, California, OptiScan Biomedical faced financial challenges, filing for Chapter 11 bankruptcy in June 2020 and subsequently converting to Chapter 7 bankruptcy in November 2020.
eNeura Therapeutics
Series B in 2005
eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.
Amnis Corporation
Series C in 2005
Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.
Alteer
Venture Round in 2005
Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.
Intact Medical
Series E in 2005
Intact Medical Corporation specializes in the design, development, and marketing of minimally invasive systems for the volumetric excision of tissue, primarily targeting diagnostic and therapeutic applications in specific cancer markets. Founded in 1998 and based in Framingham, Massachusetts, the company offers an innovative intact breast lesion excision system. This system employs a vacuum-assisted, image-guided procedure that utilizes a slender wand inserted through a small incision to extract an intact sample of suspicious breast tissue. The procedure incorporates radio frequency energy, allowing for the complete removal of identified abnormalities with minimal invasiveness. Intact Medical's mission focuses on alleviating pain, restoring health, and extending life for patients undergoing treatment.
PolyRemedy
Series A in 2005
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
EKOS Corporation is a pioneering company focused on the clinical application of ultrasound accelerated thrombolysis for the treatment of vascular thrombosis. Since its inception in 2005, EKOS has developed innovative technologies, including the EkoSonic Endovascular System, which utilizes microsonic technologies for the controlled and selective infusion of fluids specified by physicians. This system is employed by interventional radiologists, cardiologists, and vascular surgeons at leading medical institutions worldwide, enabling faster, safer, and more complete dissolution of thrombus, thereby enhancing patient outcomes in vascular care.
Aesthera is a California-based company dedicated to transforming the realm of high technology aesthetics through innovative therapies. Founded by a skilled team with extensive experience in laser research and development, Aesthera has established strong connections within the medical community and has successfully penetrated global markets for medical devices. The company specializes in light-based aesthetic treatments, notably through its breakthrough Photopneumatic Therapy (PPx), which offers a range of firsts for both physicians and patients. This includes painless treatments that do not require pre-treatments, the ability to treat legs and backs in under twenty minutes, and hygienic procedures that are significantly safer and more effective than traditional methods. Aesthera's advancements aim to enhance the quality of aesthetic care while prioritizing patient comfort and safety.
Insulet Corporation, established in 2000, specializes in the development, manufacturing, and sale of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the Omnipod System, comprises a self-adhesive, disposable, and tubeless device worn on the body for up to three days, along with a wireless, handheld personal diabetes manager. The company primarily sells its products through independent distributors, pharmacies, and directly to patients, with a presence in the United States, Canada, Europe, and the Middle East. Insulet's mission is to enhance the lives of people with diabetes by providing a user-friendly, pain-free, and automated insulin delivery solution.
Aesthera is a California-based company dedicated to transforming the realm of high technology aesthetics through innovative therapies. Founded by a skilled team with extensive experience in laser research and development, Aesthera has established strong connections within the medical community and has successfully penetrated global markets for medical devices. The company specializes in light-based aesthetic treatments, notably through its breakthrough Photopneumatic Therapy (PPx), which offers a range of firsts for both physicians and patients. This includes painless treatments that do not require pre-treatments, the ability to treat legs and backs in under twenty minutes, and hygienic procedures that are significantly safer and more effective than traditional methods. Aesthera's advancements aim to enhance the quality of aesthetic care while prioritizing patient comfort and safety.
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
Sleep Solutions
Venture Round in 2003
Sleep Solutions is a privately held company specializing in the diagnosis and evaluation of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The firm offers a home-testing service that provides a fast, cost-effective, and accurate alternative to traditional in-laboratory sleep studies. Utilizing proprietary sound analysis technology, Sleep Solutions delivers its NovaSom QSG home-diagnostic system directly to patients, enhancing convenience and comfort. In addition to diagnosis, the company also focuses on therapy and compliance management related to sleep-disordered breathing, ensuring comprehensive care for patients.
Intact Medical
Series D in 2003
Intact Medical Corporation specializes in the design, development, and marketing of minimally invasive systems for the volumetric excision of tissue, primarily targeting diagnostic and therapeutic applications in specific cancer markets. Founded in 1998 and based in Framingham, Massachusetts, the company offers an innovative intact breast lesion excision system. This system employs a vacuum-assisted, image-guided procedure that utilizes a slender wand inserted through a small incision to extract an intact sample of suspicious breast tissue. The procedure incorporates radio frequency energy, allowing for the complete removal of identified abnormalities with minimal invasiveness. Intact Medical's mission focuses on alleviating pain, restoring health, and extending life for patients undergoing treatment.
eNeura Therapeutics
Series A in 2002
eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.
Sleep Solutions
Series E in 2002
Sleep Solutions is a privately held company specializing in the diagnosis and evaluation of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The firm offers a home-testing service that provides a fast, cost-effective, and accurate alternative to traditional in-laboratory sleep studies. Utilizing proprietary sound analysis technology, Sleep Solutions delivers its NovaSom QSG home-diagnostic system directly to patients, enhancing convenience and comfort. In addition to diagnosis, the company also focuses on therapy and compliance management related to sleep-disordered breathing, ensuring comprehensive care for patients.
Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.
Sleep Solutions
Series D in 2000
Sleep Solutions is a privately held company specializing in the diagnosis and evaluation of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The firm offers a home-testing service that provides a fast, cost-effective, and accurate alternative to traditional in-laboratory sleep studies. Utilizing proprietary sound analysis technology, Sleep Solutions delivers its NovaSom QSG home-diagnostic system directly to patients, enhancing convenience and comfort. In addition to diagnosis, the company also focuses on therapy and compliance management related to sleep-disordered breathing, ensuring comprehensive care for patients.
Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.
Spinal Dynamics
Series A in 1997
Spinal Dynamics develops neuro-surgical devices for the replacement of spinal disks. The company's Bryan Cervical Disc System is an implanted prosthesis designed to replace and mimic the flexibility and shock-absorbing characteristics of natural intervertebral discs. It features a shock-absorbing elastomer that is intended to cushion the vertebrae and allow movement of the head and neck and is designed to replace the disc that is removed from the patient in cervical spine surgery.